Academic Journal
Impact of comorbidities on endobronchial valve treatment response in severe emphysema patients.
| Τίτλος: | Impact of comorbidities on endobronchial valve treatment response in severe emphysema patients. |
|---|---|
| Συγγραφείς: | Ter Haar EAMD; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. Electronic address: e.a.m.d.ter.haar@umcg.nl., Slebos DJ; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Augustijn SWS; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., van Dijk M; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Koster TD; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Klooster K; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Hartman JE; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. |
| Πηγή: | Respiratory medicine [Respir Med] 2026 Sep; Vol. 261, pp. 109046. Date of Electronic Publication: 2026 Jul 17. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2003- : Oxford : Elsevier Original Publication: London : Baillière Tindall, in association with the British Thoracic Society, [c1989- |
| Ιατρικοί όροι (MeSH): | Pulmonary Emphysema*/physiopathology , Pulmonary Emphysema*/surgery , Pulmonary Emphysema*/epidemiology , Bronchoscopy*/methods, Humans ; Female ; Male ; Aged ; Comorbidity ; Treatment Outcome ; Middle Aged ; Forced Expiratory Volume ; Quality of Life ; Prospective Studies ; Severity of Illness Index ; Follow-Up Studies ; Surveys and Questionnaires |
| Περίληψη: | Background and Objective: Endobronchial valve (EBV) therapy is an established intervention for patients with advanced emphysema with lung hyperinflation, improving pulmonary function, exercise capacity, and quality of life. Although comorbidities are highly prevalent in this patient population, their effect on EBV treatment outcomes remains unclear. This study aimed to investigate the impact of comorbidities on clinical EBV treatment response in routine clinical practice. Methods: Baseline and 12-month follow-up data were extracted from a prospective registry of EBV procedures conducted between 2016 and 2023. Comorbidities were self-reported via a questionnaire and validated with medical records. Patients were stratified by comorbidity burden: <3 and ≥ 3 comorbidities. Between-group comparisons included relative changes in forced expiratory volume in 1 s (FEV Results: In total, 202 patients were included of whom 103 (51%) had ≥3 (range 3-7) comorbidities. Both comorbidity groups demonstrated significant improvements in FEV Conclusions: Our results show that EBV treatment provided similar favourable clinical improvements with comparable safety profiles, regardless of patients their comorbidity burden. These findings underscore the importance of considering patients with comorbidities for EBV evaluation and referral. (Copyright © 2026 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:D.J. Slebos reports a relationship with PulmonX USA, MoreAir USA, Nuvaira USA, PulmAir USA, Ryme Medical USA, and Apreo USA that includes: consulting or advisory and funding grants. K. Klooster reports a relationship with PulmonX USA that includes: speaking and lecture fees. M. van Dijk reports a relationship with GSK, and Sanofi that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Bronchoscopic lung volume reduction; COPD; Efficacy; Emphysema; Endobronchial valve treatment; Safety; comorbidities |
| Entry Date(s): | Date Created: 20260717 Date Completed: 20260812 Latest Revision: 20260812 |
| Update Code: | 20260813 |
| DOI: | 10.1016/j.rmed.2026.109046 |
| PMID: | 42468857 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1532-3064 |
|---|---|
| DOI: | 10.1016/j.rmed.2026.109046 |